ArcticZymes Technologies ASALTS:0DRV 76 ROE % is 0.69% as of Mar. 2026, which is 75% below its 10-year median of 2.81. GuruFocus rates LTS:0DRV with a GF Score™ of 76/100 and a GF Value™ of kr25.75 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 1,252 Biotechnology companies, ArcticZymes Technologies ASA ranks better than 82.11% on this metric.
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
ArcticZymes Technologies ASA ROE % Related Terms
ArcticZymes Technologies ASA ROE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, ArcticZymes Technologies ASA's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ArcticZymes Technologies ASA ROE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ArcticZymes Technologies ASA's ROE % distribution charts can be found below:
* The bar in red indicates where ArcticZymes Technologies ASA's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
ArcticZymes Technologies ASA (LTS:0DRV) has a ROE % of 0.69% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on ArcticZymes Technologies ASA and its competitors. This is 75% below median its historical median of 2.81. According to the industry distribution chart, ArcticZymes Technologies ASA ranks #224 out of 1252 companies in the Biotechnology industry, placing it in the top 17.9%.
Is ArcticZymes Technologies ASA's ROE % too high?
ArcticZymes Technologies ASA's current ROE % of 0.69% is 75% below median its 10-year median of 2.81. Based on the distribution chart, ArcticZymes Technologies ASA ranks #224 out of 1252 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, ArcticZymes Technologies ASA has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ArcticZymes Technologies ASA's ROE % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, ArcticZymes Technologies ASA ranks #224 out of 1252 companies for ROE %. This places ArcticZymes Technologies ASA in the top 18% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Biotechnology company?
A good ROE % depends on the Biotechnology industry context. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on ArcticZymes Technologies ASA and its competitors. ArcticZymes Technologies ASA's current ROE % is 0.69%, which is 75% below median its own 10-year median of 2.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ArcticZymes Technologies ASA stock overvalued right now?
Based on GuruFocus' analysis, ArcticZymes Technologies ASA (LTS:0DRV) is currently considered Modestly Undervalued. The stock's GF Value™ is kr25.75, compared to a current price of kr20.90 — trading 18.8% below its estimated fair value. The current ROE % is 0.69%, which is 75% below median its 10-year median of 2.81. ArcticZymes Technologies ASA's overall GF Score™ is 76/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For ArcticZymes Technologies ASA (LTS:0DRV), the current ROE % is 0.69% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ArcticZymes Technologies ASA (LTS:0DRV) Overvalued in 2026?
Based on GuruFocus' analysis, ArcticZymes Technologies ASA stock appears to be undervalued.
The current stock price of kr20.90 is trading 18.8% below its estimated GF Value™ of kr25.75.
GuruFocus considers ArcticZymes Technologies ASA to be Modestly Undervalued.
Key valuation signals for LTS:0DRV:
ROE %: 0.69% (75% below median its 10-year median of 2.81)
GF Value™: kr25.75 vs. price of kr20.90 (18.8% below fair value)
No single metric tells the full story. See the LTS:0DRV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ArcticZymes Technologies ASA is a biotechnology company. The company is engaged in developing, producing, and marketing immune-modulating beta-glucans and novel recombinant enzymes for use in molecular research, In Vitro Diagnostics (IVD) and biomanufacturing. The company's products include Woulgan wound gel, Feed Ingredient (M-Glucan), Nutraceuticals (M-Gard), Recombinant enzymes, and others. The company reports in two operating segments, Enzymes and Corporate. Geographically, it derives a majority of revenue from the USA followed by Lithuania, Norway, Germany, France, Italy, UK, Other countries in Europe, and Rest of world.
76GF Score
Get the complete analysis for LTS:0DRV
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0DRV has been successfully added to your 
